Wendel K A, Alwood K S, Gachuhi R, Chaisson R E, Bishai W R, Sterling T R
Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore 21287, USA.
Chest. 2001 Jul;120(1):193-7. doi: 10.1378/chest.120.1.193.
To determine the incidence of paradoxical worsening of tuberculosis (TB) in HIV-infected persons.
Observational cohort study.
Public, urban TB clinic.
HIV-infected persons treated for TB between January 1, 1996, and December 31, 1999, and followed through June 30, 2000.
Patients received standard anti-TB therapy. Antiretroviral therapy was provided by primary medical providers. Patients receiving antiretroviral therapy were given nucleoside reverse transcriptase inhibitors alone or highly active antiretroviral therapy (HAART; nucleoside reverse transcriptase inhibitors in combination with a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor).
Paradoxical worsening of TB.
There were 82 TB cases in 76 patients. Paradoxical worsening was identified in 6 of 82 cases (7%; 95% confidence interval, 3 to 15%). Paradoxical worsening occurred in 3 of 28 cases (11%) in patients receiving HAART and in 3 of 44 cases (7%) in patients not receiving antiretroviral therapy (p = 0.67). Cases complicated by paradoxical worsening were more likely to have both pulmonary and extrapulmonary disease at initial diagnosis than cases without paradoxical worsening (83% vs 24%; p = 0.006). TB relapse occurred in 2 of 6 cases (33%) in patients with paradoxical worsening and in 4 of 76 cases (5%) in patients without paradoxical worsening (p = 0.06).
Paradoxical worsening of TB occurred less frequently than in previous reports and was not associated with HAART. Paradoxical worsening also appeared to be associated with an increased risk of TB relapse. Further studies are warranted to better characterize the risk factors for paradoxical worsening and the appropriate duration of anti-TB therapy in patients in whom it occurs.
确定HIV感染者中结核病(TB)矛盾性恶化的发生率。
观察性队列研究。
城市公共结核病诊所。
1996年1月1日至1999年12月31日期间接受结核病治疗并随访至2000年6月30日的HIV感染者。
患者接受标准抗结核治疗。抗逆转录病毒治疗由初级医疗服务提供者提供。接受抗逆转录病毒治疗的患者单独使用核苷类逆转录酶抑制剂或接受高效抗逆转录病毒治疗(HAART;核苷类逆转录酶抑制剂与蛋白酶抑制剂或非核苷类逆转录酶抑制剂联合使用)。
结核病的矛盾性恶化。
76例患者中有82例结核病病例。82例病例中有6例出现矛盾性恶化(7%;95%置信区间,3%至15%)。接受HAART的28例患者中有3例(11%)出现矛盾性恶化,未接受抗逆转录病毒治疗的44例患者中有3例(7%)出现矛盾性恶化(p = 0.67)。与无矛盾性恶化的病例相比,初诊时合并矛盾性恶化的病例更有可能同时患有肺部和肺外疾病(83%对24%;p = 0.006)。矛盾性恶化患者中有2例(33%)出现结核病复发,无矛盾性恶化患者中有76例中的4例(5%)出现结核病复发(p = 0.06)。
结核病矛盾性恶化比以前的报告中发生频率更低,且与HAART无关。矛盾性恶化似乎也与结核病复发风险增加有关。有必要进行进一步研究,以更好地描述矛盾性恶化的危险因素以及发生矛盾性恶化的患者抗结核治疗的合适疗程。